Qiagen NV (XTER:QIA) Moat Score: 6/10 (As of Jul. 09, 2026)


XTER:QIA Qiagen NV XTER:QIA
73 GF Score
Price €33.15
GF Value €46.41
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Qiagen NV Moat Score?

Qiagen NV XTER:QIA -2.84% 73 Moat Score is 6 as of Jul. 09, 2026. GuruFocus rates XTER:QIA with a GF Score™ of 73/100 and a GF Value™ of €46.41 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Qiagen NV ranks better than 93.98% on this metric.

Qiagen NV has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Qiagen NV has Narrow Moat: Qiagen NV has a strong narrow moat due to its leadership in molecular diagnostics, proprietary technology, and strong brand. It benefits from customer switching costs and a robust distribution network, but intense competition and regulatory challenges prevent a wide moat classification.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Qiagen NV might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

Qiagen NV  (XTER:QIA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Qiagen NV Moat Score Related Terms

XTER:QIA vs TWST, CRL, BLLN: Moat Score Comparison

For the Diagnostics & Research subindustry, Qiagen NV's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qiagen NV Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Moat Score distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Moat Score falls into.


XTER:QIA
73GF Score
Qiagen NV XTER:QIA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
Qiagen NV (XTER:QIA) has a Moat Score of 6 as of Jul. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Qiagen NV ranks #13 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 6%.
Is Qiagen NV's Moat Score too high?
Qiagen NV's current Moat Score is 6. Based on the distribution chart, Qiagen NV ranks #13 out of 216 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Qiagen NV has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's Moat Score compare to TWST and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Qiagen NV ranks #13 out of 216 companies for Moat Score. This places Qiagen NV in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Qiagen NV's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €46.41, compared to a current price of €33.15 — trading 28.6% below its estimated fair value. The current Moat Score is 6. Qiagen NV's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current Moat Score is 6 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Qiagen NV (XTER:QIA) Overvalued in 2026?

Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued. The current stock price of €33.15 is trading 28.6% below its estimated GF Value™ of €46.41. GuruFocus considers Qiagen NV to be Modestly Undervalued.

Key valuation signals for XTER:QIA:

  • Moat Score: 6
  • GF Value™: €46.41 vs. price of €33.15 (28.6% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Qiagen NV Business Description

Address Hulsterweg 82, Venlo, LI, NLD, 5912 PL
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
73GF Score

Get the complete analysis for XTER:QIA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.15
Price
€46.41
GF Value